IRISYS Discussions at CPhI China feature Gerald Yakatan, Ph.D., Chairman, CEO & Founder

– IRISYS to discuss its customized services for international clients at the leading pharmaceutical industry event in China –

San Diego, June 19, 2018 – IRISYS, LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, today announced that Gerald Yakatan, Ph.D., Chairman, CEO and founder of the company, will be heading discussions at CPhI China, a leading pharmaceutical industry event in the Asia-Pacific region. Dr. Yakatan will be joined at the company’s exhibit area by Mr. Hong Shi, an IRISYS representative based in China.

More than 45,000 pharmaceutical professionals from approximately 120 countries are expected at CPhI China, which will be held June 20 – 22, 2018 in Shanghai. Attendees will participate in a wide range of seminars to learn about the latest developments impacting the global pharmaceutical industry, including recent trends and regulations.

“IRISYS has long-standing relationships with pharmaceutical companies in China that use our services to help take their new drug candidates through the U.S. FDA regulatory process,” said Gerald Yakatan, Ph.D., Chairman, CEO and founder of the Company. “Our strengths are of particular interest to international companies that need strategic planning and regulatory guidance. IRISYS partners with our clients to advance their products from R&D and early preclinical stages to clinical trials and FDA approval.”

In addition to Chinese companies, IRISYS has experience working with clients in Australia, Japan, Korea, and Russia. IRISYS provides customized services including educating their clients’ personnel about FDA regulatory requirements and providing translations of regulatory documents. Meetings take place at the client’s location or in San Diego, California, where IRISYS maintains its headquarters, laboratories and state-of-the-art manufacturing facility.

“Like our clients, many of the CPhI China conference attendees have new pharmaceutical formulations that they need to be scaled-up and manufactured for use in U.S. clinical trials,” Yakatan noted. “IRISYS has the capabilities to support our clients’ clinical manufacturing needs. We have expertise with Good Manufacturing Practices (GMP) regulations for manufacturing a wide range of drug formulations for clinical studies and specialty pharmaceutical products.”

Visitors are welcome to discuss their needs at the IRISYS exhibit at Stand W5D92 during the CPhI China event. IRISYS can assist top global pharma companies, as well as small enterprises with no global drug development experience.

About IRISYS (

IRISYS was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specializing in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, and strategic consulting related to the drug development process. IRISYS’ custom approach to drug development is supported by the Company’s scientific and regulatory experience in moving more than 100 drug products from discovery to clinical development and commercialization

About CPhI China (

CPhI China is Asia’s leading trade and networking platform covering the entire pharma industry chain.
CPhI China 2018 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your ONE-STOP – SHOP pharmaceutical platform in Asia.

IRISYS Contacts

Louis Scotti
Vice President Business Development

Gwen Rosenberg
Rosenberg Business Communications
Please follow and like us:

Welcome to Societal™
Recro has a new name. And, with it, a renewed sense of what we can accomplish with our partners to expedite the delivery of life-changing pharmaceuticals to patients. Together, we are truly Bringing Science To Society. You will soon be able to explore our vision with the upcoming launch of our new website.